Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2021-04-11 M&A Activity
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
DiaSorin: accordo per acquisire Luminex Corporation per un valore di USD 37,00 per ciascuna azione, per complessivi USD 1,8 Miliardi circa
M&A Activity Classification · 99% confidence The document is a formal announcement dated April 11, 2021, detailing DiaSorin's agreement to acquire Luminex Corporation for approximately USD 1.8 Billion. The subject line explicitly states 'DiaSorin: accordo per acquisire Luminex Corporation' and the content discusses the strategic rationale, financial impact, and financing details of this merger/acquisition. This clearly falls under the category of M&A Activity (Merger or Takeover Announcement). The code for this is TAR.
2021-04-11 Italian
DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion
M&A Activity Classification · 98% confidence The document is an official regulatory filing (indicated by the 'Informazione Regolamentata' header and filing number) announcing a major corporate action: DiaSorin's acquisition of Luminex Corporation for approximately USD 1.8 billion. This announcement details the terms of the merger, financing arrangements (Senior Facilities Agreement), strategic rationale, and advisor roles. This content strongly aligns with an announcement regarding a significant corporate transaction, specifically a merger or takeover bid. Therefore, the most appropriate classification is 'M&A Activity' (TAR). Although it mentions a conference call and presentation slides, the core content is the definitive agreement for the transaction, not just the announcement of the report itself (which would be RPA/RNS).
2021-04-11 English
DiaSorin S.p.A.-Start up buy-back plan
Transaction in Own Shares Classification · 98% confidence The document is a formal announcement from DiaSorin S.p.A. dated April 6, 2021, titled "START UP OF THE TREASURY SHARES BUY-BACK PLAN". It explicitly details the initiation of a plan to repurchase up to 100,000 of the company's own common shares. This action falls directly under the definition of a company buying back its own shares, which corresponds to the 'Transaction in Own Shares' category (POS). Although it mentions that details are in an attachment ("Vedi allegato"), the core content is the announcement of the buy-back plan itself, not just the announcement of a report's publication (RPA). The document length (4144 chars) is substantial enough to contain the primary information, making POS a better fit than RPA.
2021-04-06 English
DiaSorin S.p.A.-Avvio programma acquisto azioni proprie
Transaction in Own Shares Classification · 98% confidence The document is a formal communication from DiaSorin S.p.A. dated April 6, 2021, titled "AVVIO PROGRAMMA DI ACQUISTO AZIONI PROPRIE DIASORIN S.P.A." (Start of DiaSorin S.p.A. Own Share Purchase Program). The content explicitly details the initiation of a share repurchase program, specifying the maximum number of shares (100,000), the purpose (to fulfill obligations under the 2020 Stock Option Plan for key executives), and the regulatory framework (EU Regulation 596/2014). This directly relates to the company buying back or selling its own shares. Therefore, the appropriate classification is Transaction in Own Shares (POS). The document length is relatively short (4718 chars) and it announces an action rather than being a comprehensive annual or interim report.
2021-04-06 Italian
DiaSorin annuncia la collaborazione strategica con Lumos Diagnostics
Regulatory Filings Classification · 95% confidence The document is an official announcement from DiaSorin, dated April 6, 2021, regarding a strategic collaboration with Lumos Diagnostics for launching a new point-of-care diagnostic platform (LIAISON® IQ) and related COVID-19 tests. The structure, including the 'Oggetto' (Subject) and the formal release format with contact information, strongly suggests a regulatory disclosure. The content is a business development/strategic announcement, not a full financial report (10-K, IR), a transcript (CT), or a dividend notice (DIV). Since it is a formal, time-sensitive announcement of a significant business event (new product launch/partnership) released via regulatory channels (indicated by 'Informazione Regolamentata'), it fits best under the general category for regulatory announcements that aren't covered by more specific codes like M&A (TAR) or Capital Changes (CAP). Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, material, non-financial regulatory announcement, although 'LTR' (Legal Proceedings Report) or 'MDA' (Management Reports) are less fitting. Since it is a formal, regulated communication ('Informazione Regolamentata'), RNS is the best fit as a general regulatory disclosure.
2021-04-06 Italian
DiaSorin announces its strategic collaboration with Lumos Diagnostics
Regulatory Filings Classification · 99% confidence The document is an official announcement from DiaSorin, dated April 6, 2021, detailing a strategic collaboration with Lumos Diagnostics to launch a new point-of-care platform (LIAISON® IQ) and initial COVID-19 related assays. The subject line explicitly states: 'DiaSorin announces its strategic collaboration with Lumos Diagnostics'. This type of announcement, detailing a significant business development, partnership, or strategic move that is not a standard periodic financial report (like 10-K or IR) or a specific transaction (like M&A/TAR or Share Issue/SHA), falls best under the general category of a Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if it involved immediate fundraising, which it does not explicitly state. Since it is a formal, non-standard regulatory disclosure about a business agreement, RNS (Regulatory Filings) is the most appropriate fallback category, as it is a general regulatory announcement that doesn't fit the more specific definitions like ER, IR, or DIV. The document length (7846 chars) is substantial enough that it is the report itself, not just a notice of publication (RPA).
2021-04-06 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.